Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
1(5%)
Results Posted
17%(2 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_2
3
16%
Ph phase_3
6
32%
Ph phase_1
1
5%
Ph early_phase_1
1
5%
Ph phase_4
4
21%
Ph not_applicable
3
16%

Phase Distribution

2

Early Stage

3

Mid Stage

10

Late Stage

Phase Distribution18 total trials
Early Phase 1First-in-human
1(5.6%)
Phase 1Safety & dosage
1(5.6%)
Phase 2Efficacy & side effects
3(16.7%)
Phase 3Large-scale testing
6(33.3%)
Phase 4Post-market surveillance
4(22.2%)
N/ANon-phased studies
3(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

12 of 15 finished

Non-Completion Rate

20.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

19

all time

Status Distribution
Active(1)
Completed(12)
Terminated(3)
Other(3)

Detailed Status

Completed12
unknown3
Withdrawn2
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
1
Success Rate
92.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (5.6%)
Phase 11 (5.6%)
Phase 23 (16.7%)
Phase 36 (33.3%)
Phase 44 (22.2%)
N/A3 (16.7%)

Trials by Status

withdrawn211%
terminated15%
completed1263%
recruiting15%
unknown316%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT04318405

Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).

Completed
NCT05913414Phase 2

Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma

Recruiting
NCT02972294Phase 3

HiFIT Study : Hip Fracture: Iron and Tranexamic Acid

Terminated
NCT03662789Phase 2

Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients

Completed
NCT02905539Phase 4

A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer

Completed
NCT03188445Phase 4

Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.

Completed
NCT04505514Phase 4

Single Dose Intravenous Iron Isomaltoside in Combination With Oral Iron vs Oral Iron Monotherapy in Patients With Anemia After Postpartum Haemorrhage

Unknown
NCT04061655Early Phase 1

Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion

Completed
NCT03470649Not Applicable

Effect of IV Iron Isomaltoside on Postoperative Anemia in Total Knee Arthroplasty Patients

Completed
NCT03094182Not Applicable

Efficacy of Intravenous Iron Therapy in Maintaining Hemoglobin Concentration on Patients Undergoing Bimaxillary Orthognathic Surgery

Unknown
NCT01927328Phase 4

Iron Replacement in Oesophagogastric Neoplasia

Unknown
NCT02172001Phase 3

A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo

Withdrawn
NCT01628770Not Applicable

Use of Iron Isomaltoside 1000 (Monofer) in Postpartum Anemia

Completed
NCT01145638Phase 3

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Completed
NCT01895205Phase 3

Treatment of Women After Severe Postpartum Haemorrhage

Completed
NCT02484768Phase 2

IV Iron Treatment of Restless Legs Syndrome

Withdrawn
NCT01599702Phase 3

Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease

Completed
NCT01895218Phase 3

Treatment of Women After Postpartum Haemorrhage

Completed
NCT01213992Phase 1

Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19